I had a fantastic experience with this company! Their website was user-friendly and provided all the information I needed. The products they offer are highly innovative and cutting-edge. I highly recommend checking them out!
Questions about Bioversys ag
What is Bioversys ag?
Bioversys ag is a biotechnology company based in Basel, Switzerland, dedicated to developing innovative solutions to combat antimicrobial resistance (AMR) and tuberculosis. The company operates through its Basel, Lille, and Guangzhou locations and focuses on creating therapies for hospital infections and drug-resistant germs.
What specific products or therapies is Bioversys ag currently developing?
The company's pipeline includes BV100, which targets carbapenem-resistant Acinetobacter baumannii infections, and alpibectir, designed for multi-drug resistant and TB-meningitis cases. Additionally, they are developing BV200 for S. aureus and BV500 for NTM infections, all aiming to address unmet medical needs in infectious conditions.
How much funding has Bioversys ag secured and what awards has it received?
Bioversys ag has secured significant funding, with CEO Dr. Marc Gitzinger having raised over $70 mio in equity financing and more than $30 mio in non-dilutive funding. The company also holds multi-award-winning status, including the Swiss Technology Award 2011 and Venture Kick 2009, reflecting its strong position in the biotech industry.
Who leads the clinical development activities at Bioversys ag?
The company's clinical development activities are led by Dr. Glenn Dale, who brings 25 years of R&D experience in infectious diseases. This leadership ensures that the company's scientific and clinical expertise is applied effectively to advancing their pipeline from lead optimization through to Phase 3 trials.
What are the current phases of Bioversys ag's clinical trials?
The company's pipeline includes BV100, which is in Phase 3 trial (RIV-TARGET) and Phase 2b trial (RIV-CARE), as well as alpibectir, which is in Phase 2b/c. These trials are actively recruiting or underway, showing the company's commitment to advancing its therapies through rigorous clinical testing.
Where are Bioversys ag's offices located and what regions do they serve?
Bioversys ag is located in Basel, Switzerland, with additional offices in Lille, France, and Guangzhou, China. These locations allow the company to serve a global market and collaborate with international partners, including Big Pharma and development organizations.
What is the core mission and global impact Bioversys ag aims to address?
The company's mission is to fight AMR using innovation to save lives and improve patient outcomes. By addressing the silent pandemic of antimicrobial resistance, Bioversys ag aims to prevent the projected 10 million annual deaths by 2050 and reduce the 13.5 US$ billion annual financial loss in the US & EU due to hospital infections.
How does Bioversys ag's diverse pipeline address unmet medical needs?
Bioversys ag is a multi-asset clinical stage company with a diverse pipeline that includes BV100, alpibectir, BV200, and BV500. This rich and diverse pipeline allows the company to tackle multiple unmet medical needs in infectious conditions, from hospital infections to tuberculosis.
What is the composition and culture of Bioversys ag's team?
The company's team is described as a world-leading group of experts with extensive scientific and clinical experience in antibiotics. This expertise is combined with entrepreneurial thinking and a strong business sense to create a dynamic and fun workplace focused on positively impacting people's lives.
What alliances and boards is Bioversys ag involved with?
Bioversys ag is part of the BEAM Alliance, a European association representing over 70 SMEs active in antimicrobial research and development. The company also serves on the Board of the AMR Industry Alliance, highlighting its role in the broader antimicrobial research community.
How does Bioversys ag handle user data and cookies on its website?
The company's website states that it uses cookies to provide a relevant experience by remembering user preferences and repeat visits. This includes necessary cookies for site functionality, analytics cookies for understanding visitor usage, and advertising cookies for measuring ad performance.
What organizations is Bioversys ag a member of?
Bioversys ag is a part of the BEAM Alliance and the AMR Industry Alliance, which are key organizations in the antimicrobial research and development field. These memberships reflect the company's commitment to collaboration and innovation in addressing global health challenges.
What regulatory designations has Bioversys ag's pipeline received?
The company's pipeline includes BV100, which has received Fast-Track Designation from the US FDA, and alpibectir, which has received Orphan Drug designation from the FDA/EMA. These designations highlight the company's focus on developing therapies for rare and serious infectious diseases.
How can I contact Bioversys ag?
You can reach Bioversys ag by e-mail at info@bioversys.com.
How is Bioversys ag rated on Trustburn?
On Trustburn, Bioversys ag has a rating of 4.1 out of 5 based on 11 reviews.
AI-generated from reviews on this page. Verify anything important with the company directly.
I've been using Bioversys ag for a while now and I must say that they are one of the best companies in the industry. Their products are of great quality and their customer service is exceptional. Highly recommended!
I've been a customer of Bioversys ag for a few months now and I must say that I am extremely satisfied with their products and services. Their customer service team is very helpful and responsive. I would highly recommend them to anyone looking for reliable products.
I recently started using the services of this company and I am really impressed. Their products are of great quality and their customer service is top-notch. Highly recommend!
๐ I am really impressed with Bioversys ag. Their products are of high quality and their customer service is excellent. I couldn't be happier with my experience. ๐
I recently started using the services of this company and I must say that I am impressed. Their products are of great quality and their customer service is exceptional. I highly recommend them.
I've had a great experience with this company. Their products are amazing and their customer service is outstanding. Highly recommended!
I have been a customer of Bioversys ag for several years now and I am extremely satisfied with their products and services. The quality of their products is unparalleled and their customer service is top-notch. I highly recommend Bioversys ag to anyone in need of their services. Keep up the great work!
I have been a loyal customer of Bioversys ag for over a year now and I can confidently say that they are one of the best companies in the industry. Their products are of great quality and their customer service is exceptional. I highly recommend them to anyone in need of their services.
๐ This company is amazing. Their products are excellent and their customer service is outstanding. I couldn't be happier with my experience. ๐
๐ Bioversys ag is an amazing company. Their products are top-notch and their customer service is excellent. I couldn't be happier with my experience. Keep up the good work! ๐
News
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
Widgets
Get the widget for your site →About Bioversys ag
Antibiotic-resistant germs are among the most important medical threats of our day and age. โท Find out more about our mission to tackle this challenge!
Bioversys AG: Tackling Antibiotic-Resistant Germs with Innovative Solutions
Antibiotic-resistant germs are a growing concern in the medical field. These superbugs have become resistant to traditional antibiotics, making it difficult for doctors to treat infections and diseases caused by them. This is where Bioversys AG comes in - a Swiss biotech company that is dedicated to developing innovative solutions to tackle antibiotic resistance.
Founded in 2008, Bioversys AG has been at the forefront of research and development of new antibiotics that can combat drug-resistant bacteria. The company's mission is to discover and develop novel small molecule drugs that target bacterial virulence factors, which are essential for bacterial survival and pathogenesis.
Bioversys AG's approach is unique because it focuses on targeting virulence factors rather than killing bacteria directly. By doing so, the company aims to reduce the selective pressure on bacteria that leads to antibiotic resistance. This approach has shown promising results in preclinical studies, with several compounds demonstrating potent activity against drug-resistant pathogens.
The company's research efforts are supported by a team of experienced scientists who specialize in microbiology, biochemistry, pharmacology, and medicinal chemistry. They work together towards discovering new compounds that can be developed into effective drugs against antibiotic-resistant germs.
Bioversys AG has also established collaborations with leading academic institutions and pharmaceutical companies worldwide. These partnerships enable the company to access cutting-edge technologies and expertise from different fields of research.
One of Bioversys AG's most significant achievements was receiving funding from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research. The funding will support the development of BV100 - one of Bioversys' lead compounds - as a treatment for multidrug-resistant Gram-negative infections.
In addition to its focus on developing new antibiotics, Bioversys AG also offers services in drug discovery and development. The company's expertise in microbiology, biochemistry, and medicinal chemistry makes it an ideal partner for pharmaceutical companies looking to develop new drugs.
Bioversys AG's commitment to tackling antibiotic resistance has not gone unnoticed. The company has received several awards and recognitions for its innovative approach to drug discovery. In 2020, Bioversys AG was named one of the top 100 Swiss startups by Startup.ch.
In conclusion, Bioversys AG is a biotech company that is dedicated to developing innovative solutions to tackle antibiotic resistance. Its unique approach of targeting bacterial virulence factors rather than killing bacteria directly has shown promising results in preclinical studies. With a team of experienced scientists and collaborations with leading academic institutions and pharmaceutical companies worldwide, Bioversys AG is well-positioned to make significant contributions towards combating antibiotic-resistant germs.
- Website
- bioversys.com
- info@bioversys.com
- Categories
- Biotechnology